Skip to Content

Join the 'Myelodysplastic Diseases' group to help and get support from people like you.

Myelodysplastic Diseases News

FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)

Posted 15 Mar 2010 by Drugs.com

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides ...

Ask a Question

Further Information

Related Condition Support Groups

Myelodysplastic Syndrome, Myeloproliferative Disorders

Related Drug Support Groups

Gleevec, Revlimid, imatinib, lenalidomide